All In Biotech

Investigational drug · Phase 3

VG081821AC

Also called: VG081821

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease (PD).

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "VG081821AC"

First trial start

2026

Jul 17, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VG081821AC", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Parkinson Disease (PD)

Approved drugs for the same conditions: Parkinson's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "VG081821AC" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Parkinson Disease (PD)

  • IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials

    Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy

  • Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials

    iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)

  • iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials

    XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.